Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research
dc.contributor.author | Grosse, Scott D. | |
dc.contributor.author | Green, Nancy S. | |
dc.contributor.author | Reeves, Sarah L. | |
dc.date.accessioned | 2020-11-04T16:01:15Z | |
dc.date.available | WITHHELD_14_MONTHS | |
dc.date.available | 2020-11-04T16:01:15Z | |
dc.date.issued | 2020-12 | |
dc.identifier.citation | Grosse, Scott D.; Green, Nancy S.; Reeves, Sarah L. (2020). "Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research." Pediatric Blood & Cancer 67(12): n/a-n/a. | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.issn | 1545-5017 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/163450 | |
dc.description.abstract | To identify people living with sickle cell disease (SCD) and study their healthcare utilization, researchers can either use clinical records linked to administrative data or use billing diagnosis codes in stand‐alone administrative databases. Correct identification of individuals clinically managed for SCD using diagnosis codes in claims databases is limited by the accuracy of billing codes in outpatient encounters. In this critical review, we assess the strengths and limitations of claims‐based SCD case‐finding algorithms in stand‐alone administrative databases that contain both inpatient and outpatient records. Validation studies conducted using clinical records and newborn screening for confirmation of SCD case status have found that algorithms that require three or more nonpharmacy claims or one inpatient claim plus two or more outpatient claims with SCD codes show acceptable accuracy (positive predictive value and sensitivity) in children and adolescents. Future studies might seek to assess the accuracy of case‐finding algorithms over the lifespan. | |
dc.publisher | Agency for Healthcare Research and Quality | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | Medicaid | |
dc.subject.other | sickle cell disease | |
dc.subject.other | healthcare use | |
dc.subject.other | diagnostic codes | |
dc.subject.other | billing codes | |
dc.title | Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Pediatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163450/2/pbc28703_am.pdf | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/163450/1/pbc28703.pdf | en_US |
dc.identifier.doi | 10.1002/pbc.28703 | |
dc.identifier.source | Pediatric Blood & Cancer | |
dc.identifier.citedreference | Paulukonis ST, Harris WT, Coates TD, et al. Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH). Pediatr Blood Cancer. 2014; 61 ( 12 ): 2271 ‐ 2276. | |
dc.identifier.citedreference | Wilson‐Frederick SM, Hulihan M, Blaz J, Young BM. Prevalence of Sickle Cell Disease among Medicare Fee‐for‐Service Beneficiaries. Baltimore: CMS Office of Minority Health Data Highlight; 2019. | |
dc.identifier.citedreference | California SCDC Data, 2016: Map and Figures. 2019; https://www.cdc.gov/ncbddd/hemoglobinopathies/scdc-state-data/california-2016.html. Accessed October 2, 2019. | |
dc.identifier.citedreference | Kayle M, Valle J, Paulukonis S, et al. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease. Pediatr Blood Cancer. 2020; 67 ( 5 ): e28152. | |
dc.identifier.citedreference | Zhou J, Han J, Nutescu EA, Gordeuk VR, Saraf SL, Calip GS. Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6‐year population‐based cohort study. Br J Haematol. 2018; 182 ( 2 ): 259 ‐ 270. | |
dc.identifier.citedreference | Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS. Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf. 2018; 27 ( 5 ): 479 ‐ 486. | |
dc.identifier.citedreference | Reeves SL, Jary HK, Gondhi JP, Kleyn M, Wagner AL, Dombkowski KJ. Pneumococcal vaccination coverage among children with sickle cell anemia, sickle cell trait, and normal hemoglobin. Pediatr Blood Cancer. 2018; 65 ( 10 ): e27282. | |
dc.identifier.citedreference | Anders DG, Tang F, Ledneva T, et al. Hydroxyurea use in young children with sckle cell anemia in New York state. Am J Prev Med. 2016; 51 ( 1 Suppl 1 ): S31 ‐ 38. | |
dc.identifier.citedreference | Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011; 86 ( 3 ): 273 ‐ 277. | |
dc.identifier.citedreference | Stettler N, McKiernan CM, Adejoro OO, Walczak NB. Proportion of adults with sickle cell anemia and pain crises receiving hydroxyurea. JAMA. 2015; 313 ( 16 ): 1671 ‐ 1672. | |
dc.identifier.citedreference | Lanzkron S, Haywood C, Jr, Fagan PJ, Rand CS. Examining the effectiveness of hydroxyurea in people with sickle cell disease. J Health Care Poor Underserved. 2010; 21 ( 1 ): 277 ‐ 286. | |
dc.identifier.citedreference | Stallworth JR, Jerrell JM, Tripathi A. Cost‐effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease. Am J Hematol. 2010; 85 ( 10 ): 795 ‐ 797. | |
dc.identifier.citedreference | Castro O, Nouraie M, Oneal P. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014; 167 ( 5 ): 687 ‐ 691. | |
dc.identifier.citedreference | Reeves SL, Madden B, Freed GL, Dombkowski KJ. Transcranial Doppler screening among children and adolescents with sickle cell anemia. JAMA Pediatr. 2016; 170 ( 6 ): 550 ‐ 556. | |
dc.identifier.citedreference | Reeves SL, Fullerton HJ, Cohn LM, et al. Missed opportunities for transcranial Doppler screening among children with sickle cell disease. Clin Pediatr (Phila). 2016; 55 ( 12 ): 1093 ‐ 1099. | |
dc.identifier.citedreference | Reeves SL, Braun TM, Dombkowski KJ, Fullerton HJ, Boulton ML, Lisabeth LD. The role of neighborhoods in the receipt of transcranial Doppler screening among children with sickle cell disease. J Pediatr Hematol Oncol. 2015; 37 ( 4 ): 269 ‐ 273. | |
dc.identifier.citedreference | Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. Am J Med Qual. 1999; 14 ( 6 ): 270 ‐ 277. | |
dc.identifier.citedreference | Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims‐based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res. 2004; 39 ( 6 Pt 1 ): 1839 ‐ 1857. | |
dc.identifier.citedreference | Crego N, Douglas C, Bonnabeau E, et al. Sickle‐cell disease co‐management, health care utilization, and hydroxyurea use. J Am Board Fam Med. 2020; 33 ( 1 ): 91 ‐ 105. | |
dc.identifier.citedreference | Raphael JL, Dietrich CL, Whitmire D, Mahoney DH, Mueller BU, Giardino AP. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer. 2009; 52 ( 2 ): 263 ‐ 267. | |
dc.identifier.citedreference | Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: prevalence and resource utilization. PLoS One. 2019; 14 ( 7 ): e0214355. | |
dc.identifier.citedreference | Shah N, Bhor M, Xie L, et al. Evaluation of vaso‐occlusive crises in United States sickle cell disease patients: a retrospective claims‐based study. J Health Econ Outcomes Rese. 2019; 6 ( 3 ): 106 ‐ 117. | |
dc.identifier.citedreference | Shah N, Bhor M, Xie L, et al. Treatment patterns and economic burden of sickle‐cell disease patients prescribed hydroxyurea: a retrospective claims‐based study. Health Qual Life Outcomes. 2019; 17 ( 1 ): 155. | |
dc.identifier.citedreference | Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017; 376 ( 16 ): 1561 ‐ 1573. | |
dc.identifier.citedreference | Amendah DD, Mvundura M, Kavanagh PL, Sprinz PG, Grosse SD. Sickle cell disease‐related pediatric medical expenditures in the U.S. Am J Prev Med. 2010; 38 ( 4 Suppl ): S550 ‐ 556. | |
dc.identifier.citedreference | Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer. 2009; 53 ( 4 ): 642 ‐ 646. | |
dc.identifier.citedreference | Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010; 303 ( 13 ): 1288 ‐ 1294. | |
dc.identifier.citedreference | Grosse SD, Boulet SL, Amendah DD, Oyeku SO. Administrative data sets and health services research on hemoglobinopathies: a review of the literature. Am J Prev Med. 2010; 38 ( 4 Suppl ): S557 ‐ 567. | |
dc.identifier.citedreference | Fingar KR, Owens PL, Reid LD, Mistry K, Barrett ML. Characteristics of Inpatient Hospital Stays Involving Sickle Cell Disease, 2000–2016: HCUP Statistical Brief #251. Rockville: Agency for Healthcare Research and Quality; 2019. | |
dc.identifier.citedreference | Singh A, Mora J, Panepinto JA. Identification of patients with hemoglobin SS/Sbeta(0) thalassemia disease and pain crises within electronic health records. Blood Adv. 2018; 2 ( 11 ): 1172 ‐ 1179. | |
dc.identifier.citedreference | Michalik DE, Taylor BW, Panepinto JA. Identification and validation of a sickle cell disease cohort within electronic health records. Acad Pediatr. 2017; 17 ( 3 ): 283 ‐ 287. | |
dc.identifier.citedreference | Schopper HK, D’Esposito CF, Muus JS, Kanter J, Meyer TA. Childhood hearing loss in patients with sickle cell disease in the United States. J Pediatr Hematol Oncol. 2019; 41 ( 2 ): 124 ‐ 128. | |
dc.identifier.citedreference | Centers for Medicare and Medicaid Services. Chronic conditions data warehouse condition categories. 2019; https://www.ccwdata.org/web/guest/condition-categories. Accessed February 18, 2019. | |
dc.identifier.citedreference | Ronald LA, Ling DI, FitzGerald JM, et al. Validated methods for identifying tuberculosis patients in health administrative databases: systematic review. Int J Tuberc Lung Dis. 2017; 21 ( 5 ): 517 ‐ 522. | |
dc.identifier.citedreference | Worth RM, Mytinger RE. Medical insurance claims as a source of data for research: accuracy of diagnostic coding. Hawaii Med J. 1996; 55 ( 1 ): 9 ‐ 11. | |
dc.identifier.citedreference | Andrade SE, Scott PE, Davis RL, et al. Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiol Drug Saf. 2013; 22 ( 1 ): 7 ‐ 15. | |
dc.identifier.citedreference | Metcalfe A, Sibbald B, Lowry RB, Tough S, Bernier FP. Validation of congenital anomaly coding in Canada’s administrative databases compared with a congenital anomaly registry. Birth Defects Res A Clin Mol Teratol. 2014; 100 ( 2 ): 59 ‐ 66. | |
dc.identifier.citedreference | Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010; 63 ( 2 ): 223 ‐ 228. | |
dc.identifier.citedreference | McPheeters ML, Sathe NA, Jerome RN, Carnahan RM. Methods for systematic reviews of administrative database studies capturing health outcomes of interest. Vaccine. 2013; 31 ( Suppl 10 ): K2 ‐ 6. | |
dc.identifier.citedreference | Sickbert‐Bennett EE, Weber DJ, Poole C, MacDonald PD, Maillard JM. Completeness of communicable disease reporting, North Carolina, USA, 1995–1997 and 2000–2006. Emerg Infect Dis. 2011; 17 ( 1 ): 23 ‐ 29. | |
dc.identifier.citedreference | Mullooly JP, Donahue JG, DeStefano F, Baggs J, Eriksen E. V. S. D. Data Quality Working Group. Predictive value of ICD‐9‐CM codes used in vaccine safety research. Methods Inf Med. 2008; 47 ( 4 ): 328 ‐ 335. | |
dc.identifier.citedreference | Reeves SL MB, Shevrin CA, McCormick J, Freed GL, Dombkowski KJ, Antibiotic prophylaxis among children with sickle cell anemia. 2017; http://chear.org/sites/default/files/stories/pdfs/sca_antibiotic_measure_testing.pdf. Accessed May 2, 2019. | |
dc.identifier.citedreference | Reeves S, Garcia E, Kleyn M, et al. Identifying sickle cell disease cases using administrative claims. Acad Pediatr. 2014; 14 ( 5 Suppl ): S61 ‐ 67. | |
dc.identifier.citedreference | Eisenbrown K, Nimmer M, Brousseau DC. The accuracy of using ICD‐9‐CM codes to determine genotype and fever status of patients with sickle cell disease. Pediatr Blood Cancer. 2015; 62 ( 5 ): 924 ‐ 925. | |
dc.identifier.citedreference | Snyder AB, Lane PA, Zhou M, Paulukonis ST, Hulihan MM. The accuracy of hospital ICD‐9‐CM codes for determining sickle cell disease genotype. J Rare Dis Res Treat. 2017; 2 ( 4 ): 39 ‐ 45. | |
dc.identifier.citedreference | Snyder AB, Zhou M, Theodore R, Quarmyne MO, Eckman J, Lane PA. Improving an administrative case definition for longitudinal surveillance of sickle cell disease. Public Health Rep. 2019;134(3):274‐281. | |
dc.identifier.citedreference | Benchimol EI, Manuel DG, To T, Griffiths AM, Rabeneck L, Guttmann A. Development and use of reporting guidelines for assessing the quality of validation studies of health administrative data. J Clin Epidemiol. 2011; 64 ( 8 ): 821 ‐ 829. | |
dc.identifier.citedreference | Kuhlthau K, Ferris TG, Beal AC, Gortmaker SL, Perrin JM. Who cares for Medicaid‐enrolled children with chronic conditions. Pediatrics. 2001; 108 ( 4 ): 906 ‐ 912. | |
dc.identifier.citedreference | Sox CM, Cooper WO, Koepsell TD, DiGiuseppe DL, Christakis DA. Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease. JAMA. 2003; 290 ( 8 ): 1057 ‐ 1061. | |
dc.identifier.citedreference | Eckrich MJ, Wang WC, Yang E, et al. Adherence to transcranial Doppler screening guidelines among children with sickle cell disease. Pediatr Blood Cancer. 2013; 60 ( 2 ): 270 ‐ 274. | |
dc.identifier.citedreference | Warren MD, Arbogast PG, Dudley JA, et al. Adherence to prophylactic antibiotic guidelines among Medicaid infants with sickle cell disease. Arch Pediatr Adolesc Med. 2010; 164 ( 3 ): 298 ‐ 299. | |
dc.identifier.citedreference | Shankar SM, Arbogast PG, Mitchel E, Cooper WO, Wang WC, Griffin MR. Medical care utilization and mortality in sickle cell disease: a population‐based study. Am J Hematol. 2005; 80 ( 4 ): 262 ‐ 270. | |
dc.identifier.citedreference | Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007; 44 ( 11 ): 1428 ‐ 1433. | |
dc.identifier.citedreference | Bundy DG, Muschelli J, Clemens GD, et al. Preventive care delivery to young children with sickle cell disease. J Pediatr Hematol Oncol. 2016; 38 ( 4 ): 294 ‐ 300. | |
dc.identifier.citedreference | Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States. Am J Hematol. 2008; 83 ( 4 ): 263 ‐ 270. | |
dc.identifier.citedreference | Kauf TL, Coates TD, Huazhi L, Mody‐Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009; 84 ( 6 ): 323 ‐ 327. | |
dc.identifier.citedreference | Beverung LM, Brousseau D, Hoffmann RG, Yan K, Panepinto JA. Ambulatory quality indicators to prevent infection in sickle cell disease. Am J Hematol. 2014; 89 ( 3 ): 256 ‐ 260. | |
dc.identifier.citedreference | Brousseau DC, Richardson T, Hall M, et al. Hydroxyurea use for sickle cell disease among Medicaid‐enrolled children. Pediatrics. 2019; 144 ( 1 ):e20183285. | |
dc.identifier.citedreference | Leschke J, Panepinto JA, Nimmer M, Hoffmann RG, Yan K, Brousseau DC. Outpatient follow‐up and rehospitalizations for sickle cell disease patients. Pediatr Blood Cancer. 2012; 58 ( 3 ): 406 ‐ 409. | |
dc.identifier.citedreference | Ritho J, Liu H, Hartzema AG, Lottenberg R. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Am J Hematol. 2011; 86 ( 10 ): 888 ‐ 890. | |
dc.identifier.citedreference | Bundy DG, Abrams MT, Strouse JJ, Mueller CH, Miller MR, Casella JF. Transcranial Doppler screening of Medicaid‐insured children with sickle cell disease. J Pediatr. 2015; 166 ( 1 ): 188 ‐ 190. | |
dc.identifier.citedreference | Bundy DG, Muschelli J, Clemens GD, et al. Ambulatory care connections of Medicaid‐insured children with sickle cell disease. Pediatr Blood Cancer. 2012; 59 ( 5 ): 888 ‐ 894. | |
dc.identifier.citedreference | Han J, Zhou J, Kondragunta V, et al. Erythropoiesis‐stimulating agents in sickle cell anaemia. Br J Haematol. 2018; 182 ( 4 ): 602 ‐ 605. | |
dc.identifier.citedreference | Ballas SK, Kanter J, Agodoa I, et al. Opioid utilization patterns in United States individuals with sickle cell disease. Am J Hematol. 2018; 93 ( 10 ): E345 ‐ E347. | |
dc.identifier.citedreference | Badawy SM, Payne AB. Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. Blood Adv. 2019; 3 ( 21 ): 3297 ‐ 3306. | |
dc.identifier.citedreference | Boulet SL, Okoroh EM, Azonobi I, Grant A, Craig Hooper W. Sickle cell disease in pregnancy: maternal complications in a Medicaid‐enrolled population. Matern Child Health J. 2013; 17 ( 2 ): 200 ‐ 207. | |
dc.identifier.citedreference | Singh A, Yan K, Brandow AM, Panepinto JA. Longitudinal trend in emergency department reliance for pain among sickle cell disease patients in Wisconsin. J Pediatr Hematol Oncol. 2019; 41 ( 7 ): e438 ‐ e442. | |
dc.identifier.citedreference | Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A. Association between vaso‐occlusive crises and opioid prescriptions among patients with sickle cell disease: a retrospective claims‐based study. J Health Econ Outcomes Res. 2020; 7 ( 1 ): 94 ‐ 101. | |
dc.identifier.citedreference | Reeves SL, Fullerton HJ, Dombkowski KJ, Boulton ML, Braun TM, Lisabeth LD. Physician attitude, awareness, and knowledge regarding guidelines for transcranial Doppler screening in sickle cell disease. Clin Pediatr (Phila). 2015; 54 ( 4 ): 336 ‐ 345. | |
dc.identifier.citedreference | Nero AC, Akuete K, Leasure Reeves S, Dombkowski KJ. Pneumococcal vaccination rates in children with sickle cell disease. J Public Health Manag Pract. 2014; 20 ( 6 ): 587 ‐ 590. | |
dc.identifier.citedreference | Reeves SL, Tribble AC, Madden B, Freed GL, Dombkowski KJ. Antibiotic prophylaxis for children with sickle cell anemia. Pediatrics. 2018; 141 ( 3 ). pii: e20172182. | |
dc.identifier.citedreference | Paulukonis ST, Feuchtbaum LB, Coates TD, et al. Emergency department utilization by Californians with sickle cell disease, 2005–2014. Pediatr Blood Cancer. 2017; 64 ( 6 ): e26390. | |
dc.identifier.citedreference | Wilson‐Frederick SM, Hulihan M, Anderson KK. Prevalence of Sickle Cell Disease among Medicaid Beneficiaries in 2012. Baltimore: CMS Office of Minority Health Data Highlight: 2019. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.